eli lilly retatrutide Lilly's cuts weight by 17% in diabetes trial Eli Lillys retatrutide what is

Endo K, Kasagi K, Konishi J, Ikekubo K, Okuno T, Takeda Y, et al

Data extraction Two designated authors (AM and SS) meticulously extracted pertinent data from the included studies, including authorship details, publication timeline, samples of the study, mean demographic parameters (e.g., age, sex, baseline weight, and baseline BMI), type of bariatric surgery, prevalent background diseases, type of the GLP-1RAs therapy, the time of the initiation of the medical treatment, laboratory indices, amount of weight-change, and a comprehensive array of outcome measures, such as nausea, vomiting, diarrhea, and serious adverse events

Kooltheat N, Sranujit RP, Chumark P, Potup P, Laytragoon-Lewin N, Usuwanthim K

GLP-1 medications slow gastric emptying